TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02836574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: Autologous selected renal cells (SRC).
Study: NCT03680664

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: MBSR
Description: After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice.
Study: NCT02836574

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal Biopsy
Description: a procedure in which a small sample of kidney tissue is removed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Biopsy
Description: a procedure in which a small sample of kidney tissue is removed
Study: NCT04698538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JASPER
Description: JASPER is a naturalistic, developmental, behavioral intervention (NDBI) that focuses on developing social communication and language skills in the context of a play based intervention.
Study: NCT03823144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic Microscopy
Description: Undergo Intravital microscopy (IVM), which allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Sodium Injection
Description: Given IV as part of IVM procedure
Study: NCT03068325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TF-EAT
Study: NCT03112941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control group
Description: Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen group
Description: Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
Study: NCT03652805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPL344
Description: The study is designed to determine the tolerability, safety and PK of IPL344 administered I.V. once a day for 28 days and to identify the maximum tolerated dose.~All patients enrolled will have a documented history of ALS disease prior to study enrollment.~Treatment will start with 1.7mg/kg with dose escalation by 0.5 mg/kg every 3-4 days and will increase to the maximum dose of 3.2mg/kg. Day 1 to Day 28 patients will be on active treatment.~After completion of 28 treatment days, participants who will choose to continue treatment (at the investigator's discretion), will be enrolled in a follow-up study. Participants that discontinue treatment after Day 28 will be followed up by a nurse phone call and return to the clinic for a final visit on Day 56 from the first dose.
Study: NCT01555190

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: myo-inositol 1500 gr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: myo-inositol 2000 gr + folic acid 200 mcg
Study: NCT00985985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: 2 mg or 4 mg nicotine lozenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: 2 mg or 4 mg nicotine lozenge
Study: NCT03745690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image-Guided Surgery
Description: Undergo near-infrared image guided surgical resection
Study: NCT00985985

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lozenge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo lozenge
Study: NCT03113929

Intervention type: RADIATION
Intervention: MRI
Description: Research MRI
Study: NCT03745690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Drug
Description: Given IV
Study: NCT00319592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChimeriVax™-JE vaccine
Description: 0.5 mL, subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: JE-VAX® vaccine
Description: 1.0 mL, subcutaneously
Study: NCT03615144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan 70 mg/m2/day x 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan 70 mg/m2/day x 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa
Description: Thiotepa 7.5 mg/kg/day x 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa
Description: Thiotepa 7.5 mg/kg/day x 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofarabine
Description: Clofarabine 20-30 mg/m2/day x 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2/day x 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
Description: antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
Description: antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CliniMACS reagents
Description: Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CliniMACS reagents
Description: Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.
Study: NCT04448457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil Sublingual Tablet
Description: 15 mcg with lockout interval of 20 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone oral tablet and oxycodone extended-release oral tablet
Description: Oxycodone hydrochloride 5 mg and Oxycodone extended-release 10 mg
Study: NCT01895881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01707108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Implant (MIS Technologies)
Description: MIS Technologies Ltd. C1 Dental implants
Study: NCT01481662

Intervention type: DEVICE
Intervention: Diffusion tensor magnetic resonance imaging of the brain
Description: Diffusion tensor magnetic resonance imaging of the brain will be obtained to more carefully study the cerebral microvasculopathy of the disease.
Study: NCT04080557

Intervention type: OTHER
Intervention: Surgery
Description: All patients treated electively for an abdominal aortic aneurysm (AAA) by open repair and patients undergoing emergency treatment for a ruptured AAA between 2013 and 2018.
Study: NCT04024111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KONTAKT(c)
Description: KONTAKT is a manualized Social skills group training program designed for children and adolescents on the Autism Spectrum aimed at improving communication, social interaction skills, the severity of ASD symptoms, and the ability to empathise and adapt in a group setting. The KONTAKT participants (4-8 participants) meet face to face weekly for 16 weeks for 75 minutes facilitated by two health professionals with experience of running groups for autistic children

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Art group
Description: Art program, a manualized Art group delivered in a social format, has been designed for children on the Autism Spectrum delivered by health professionals with experience of running social groups for Autistic children. The Art program's participants (4-8 participants) meet face to face weekly for 16 weeks for 75 minutes.
Study: NCT02682823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-1000 G2
Description: Tocilizumab will be administered using the AI-1000 G2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-1000 G2
Description: Tocilizumab will be administered using the AI-1000 G2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-1000 G2
Description: Tocilizumab will be administered using the AI-1000 G2.
Study: NCT00212381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: di indolylmethane (DIM)
Description: This is the agent being studies. Similar agents have been reported to have potential activity.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red rice bran
Description: this will act as the active comparator. The sponsor provided this as the placebo arm since it is a filler component of their DIM capsules
Study: NCT02682823

Intervention type: DEVICE
Group type: OTHER
Intervention: AI-1000 G2
Description: Tocilizumab will be administered using the AI-1000 G2.

Intervention type: DEVICE
Group type: OTHER
Intervention: AI-1000 G2
Description: Tocilizumab will be administered using the AI-1000 G2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
Study: NCT03520595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arnica 200 drug 3 pills,3 times daily for 3 days
Description: CLP with ostectomy done in patients whose biologic width and crown height is insufficient
Study: NCT02682823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.

Intervention type: DRUG
Group type: OTHER
Intervention: Tocilizumab
Description: Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.

Intervention type: DRUG
Group type: OTHER
Intervention: Tocilizumab
Description: Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
Study: NCT01259349

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: one percent ultrasound power in CMICS
Description: Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at one percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 40 percent ultrasound power in CMICS
Description: Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at 40 percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
Study: NCT00613691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-1620
Description: SPI-1620 in escalating doses from 0.5 μg/m2 intravenous over sixty seconds
Study: NCT04053712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: GlucaGen(R), Novo Nordisk, DK

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop system
Description: Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Closed-loop system
Description: Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
Study: NCT01137110

Intervention type: OTHER
Group type: OTHER
Intervention: Brief LEV
Description: Levetiracetam 1000mg BID x 3 days for prophylaxis

Intervention type: OTHER
Group type: OTHER
Intervention: Extended LEV
Description: Levetiracetam 1000mg BID for length of hospital stay for prophylaxis
Study: NCT05927740

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Optic coherence tomography
Description: Every participant was subjected to a comprehensive ophthalmologic examination which included measuring auto-refraction (average of three values, Topcon Autorefractometer model KM 8900, Japan), uncorrected visual acuity with cycloplegic refraction (with 0.5% cyclopentolate HCl), and IOP in millimeters of mercury (mmHg, Goldmann applanation tonometer). Moreover, slit-lamp biomicroscopy (HaagStreit, Bern, Switzerland) was performed, concentrating on potential corneal scarring and/or lenticular opacities.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Optic coherence tomography
Description: Every participant was subjected to a comprehensive ophthalmologic examination which included measuring auto-refraction (average of three values, Topcon Autorefractometer model KM 8900, Japan), uncorrected visual acuity with cycloplegic refraction (with 0.5% cyclopentolate HCl), and IOP in millimeters of mercury (mmHg, Goldmann applanation tonometer). Moreover, slit-lamp biomicroscopy (HaagStreit, Bern, Switzerland) was performed, concentrating on potential corneal scarring and/or lenticular opacities.
Study: NCT03108768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid (Successor of Phonak Virto V)
Description: The successor of Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing Aid (Phonak Virto V)
Description: Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
Study: NCT01769508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU, 225 mg/m2 IVCI, during XRT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin, 85 mg/m2 IV, Days 1, 15, 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib, Continuous PO daily dosing during XRT, dose determined during lead in portion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy, 50.4 Gy (1.8 Gy/day or 28 fractions) M-F, Weeks1-6
Study: NCT03400709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetylcysteine
Description: Oral administration of drug, before, during and after Chemoradiotherapy including Cisplatin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo treatment
Study: NCT04288687

Intervention type: DRUG
Group type: OTHER
Intervention: Niraparib Pill
Description: Niraparib 200 mg by mouth daily (2 x 100 mg pills)
Study: NCT01281670

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vibration
Description: 8 week vibration
Study: NCT02261948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
Study: NCT03758222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XFLO Expander System
Description: Implantation and retrieval of the XFLO Expander System in the prostatic urethra to treat benign prostatic hyperplasia (BPH)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XFLO Expander System
Description: Implantation and retrieval of the XFLO Expander System in the prostatic urethra to treat benign prostatic hyperplasia (BPH)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XFLO Expander System
Description: Implantation and retrieval of the XFLO Expander System in the prostatic urethra to treat benign prostatic hyperplasia (BPH)
Study: NCT02990936

Intervention type: OTHER
Intervention: Tumor delineation
Description: Measurement of tumor volume and neck nodes volume on a diagnostic CT and a pre-treatment CT by computerized delineation in order to calculate tumor growth velocity and tumor doubling time and describe tumoral kinetics patterns
Study: NCT03470155

Intervention type: PROCEDURE
Intervention: mitral valve repair
Description: operative reconstruction
Study: NCT04101682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Administered by an anesthesiologist or certified nurse anesthetist, under ultrasound guidance a catheter placed overlying the nerve sheath. This catheter is then connected to a device with a reservoir that administers local anesthetic at a set rate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Administered by an anesthesiologist or certified nurse anesthetist, under ultrasound guidance a catheter placed overlying the nerve sheath. This catheter is then connected to a device with a reservoir that administers local anesthetic at a set rate.
Study: NCT04079517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: A registered SERM drug, Tamoxifen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: A registered SERM drug, Tamoxifen.
Study: NCT03749967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
Study: NCT04015089

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed formula (pHF)
Description: Infant formula with partially hydrolyzed protein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard formula (SF)
Description: Infant formula with intact protein